TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1612040

Group type: EXPERIMENTAL
Intervention: Simethicone 65 mg in 90 ml of water
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Simethicone 65 mg in 30 ml of water
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Simethicone 195 mg in 90 ml of water
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Simethicone (any dosage)
Number of subjects: 330
Study: 6374678

Group type: EXPERIMENTAL
Intervention: Flupenthixol (1 to 2 mg per day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diazepam (5 to 10 mg per day)
Number of subjects: 120
Study: 30879470

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR) consisting of 10 therapy sessions over 3 months, followed by four maintenance sessions over 6 months.
Number of subjects: 475

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 475
Study: 28689852

Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral therapy for co-occurring opioid use disorder and anxiety disorders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active comparison treatment targeting opioid use disorder alone
Number of subjects: 0
Study: 25975527

Group type: EXPERIMENTAL
Intervention: Clip closure of defects after endoscopic resection
Number of subjects: 348

Group type: COMPARATOR
Intervention: No closure of defects after endoscopic resection
Number of subjects: 348
Study: 24127679

Group type: EXPERIMENTAL
Intervention: Tristel Fuse (chlorine dioxide)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cidex OPA (ortho-phthaldehyde)
Number of subjects: 180
Study: 22687658

Group type: EXPERIMENTAL
Intervention: PNF stretching (contract-release technique)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PNF vs Static
Number of subjects: 45
Study: 19114907

Group type: EXPERIMENTAL
Intervention: Early vital capacity maneuver (VCM)
Number of subjects: 50
Study: 16772353

Group type: EXPERIMENTAL
Intervention: Ghrelin (10 pmol/kg.min) infusion for 180 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GH substitution in GH-deficient patients
Number of subjects: 0
Study: 15352043

Group type: EXPERIMENTAL
Intervention: alpha-carotene (highest quartile)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: dietary intakes of alpha-carotene
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: dietary intakes of vitamin A
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: beta-carotene (highest quartile)
Number of subjects: 834
Study: 10694094

Group type: EXPERIMENTAL
Intervention: Specific antiglycolipid antibodies in serum and circulating immune complexes
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: IgG antibody levels against glycolipid LOS
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: IgG antibody against LOS
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combination of antigens tested in serum
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Detection of immune complexes and IgG antibodies against glycolipid antigens
Number of subjects: 53
Study: 9333047

Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fed (high-fat meal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fasting with sucralfate
Number of subjects: 24
Study: 1304698

Group type: EXPERIMENTAL
Intervention: Fansimef
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Lariam
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Fansidar
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 567
Study: 4075722

Group type: EXPERIMENTAL
Intervention: Colon cleansing
Number of subjects: 133
Study: 3233058

Group type: EXPERIMENTAL
Intervention: Amoxicillin 40 mg.kg‐1 every 12 hours by IV route
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amoxicillin 40 mg.kg‐1 every 12 hours by oral route
Number of subjects: 21
Study: 29247809

Group type: EXPERIMENTAL
Intervention: IV diclofenac (two doses of 75mg in the first 24h after diagnosis)
Number of subjects: 34

Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 34
Study: 28111801

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg and 150 mg
Number of subjects: 0
Study: 25687568

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus salivarius UCC118)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 23791063

Group type: EXPERIMENTAL
Intervention: Tulobuterol patch
Number of subjects: 92

Group type: COMPARATOR
Intervention: Oral salbutamol sulfate
Number of subjects: 92
Study: 21612452

Group type: EXPERIMENTAL
Intervention: Experimental green tea extract (40 mL, rinsed for 1 minute, three times a day for a week)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo mouth rinse (40 mL, rinsed for 1 minute, three times a day for a week)
Number of subjects: 66
Study: 18209254

Group type: EXPERIMENTAL
Intervention: Practice moderate-intensity walking (55%-70% of maximum heart rate)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No practice
Number of subjects: 75
Study: 16757422

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement in patients with recruitable myocardium (group 1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Aortic valve replacement in patients without recruitable myocardium (group 2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison of functional capacity improvement between groups
Number of subjects: 27
Study: 14535872

Group type: EXPERIMENTAL
Intervention: OAC7 (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d. for 7 days)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: OAC14 (clarithromycin 500 mg b.d. for 14 days)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: OAM14 (metronidazole 500 mg b.d. for 14 days)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Susceptibility-based treatment (clarithromycin-susceptible strains: OAC14, others: OAM14)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Clarithromycin-susceptible strains
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant strains
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Metronidazole-susceptible strains
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Metronidazole-resistant strains
Number of subjects: 287
Study: 10944140

Group type: EXPERIMENTAL
Intervention: Audiotaped initial consultation
Number of subjects: 201

Group type: COMPARATOR
Intervention: No audiotaped initial consultation (control group)
Number of subjects: 201
Study: 8558189

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 over 3 hours, repeated every 3 weeks for a maximum of nine cycles
Number of subjects: 51
Study: 1385682

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.03% (21 micrograms per nostril)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.03% (42 micrograms per nostril)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 6425480

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with total parenteral nutrition (120% of estimated energy requirements, 3.75% or 22.5% as lipid, amino acids 2.5 gm/120 kcal)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Post-parenteral nutrition period
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (baseline measurements before intervention)
Number of subjects: 11
Study: 31077726

Group type: EXPERIMENTAL
Intervention: Wearable cardioverter-defibrillator (WCD)
Number of subjects: 0
Study: 29514712

Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg q4w
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg q2w
Number of subjects: 122
Study: 26271449

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (deflated cuff placed on upper arm for 30 min)
Number of subjects: 100
Study: 24434117

Group type: EXPERIMENTAL
Intervention: Creatine (20 g/d for 7 d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22429800

Group type: EXPERIMENTAL
Intervention: Semuloparin
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1150
Study: 20181654

Group type: EXPERIMENTAL
Intervention: Minocycline (150 mg to 250 mg po BID) as add-on therapy to standard care for up to 10 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Minocycline (10-100 mg kg(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxycycline (10-100 mg kg(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Minocycline and doxycycline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 12
Study: 18820095

Group type: EXPERIMENTAL
Intervention: Low-frequency maintenance exercise (1 time per week)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-frequency maintenance exercise (4 times per week)
Number of subjects: 36
Study: 16019358

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE) alone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CEE alone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CEE
Number of subjects: 35

Group type: COMPARATOR
Intervention: Progestogens (medroxyprogesterone acetate, desogestrel, norethisterone)
Number of subjects: 35
Study: 11573655

Group type: EXPERIMENTAL
Intervention: Enalaprilat (ACEI) for 2 days, n=7
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group, n=7
Number of subjects: 14
Study: 9776034

Group type: EXPERIMENTAL
Intervention: Periosteal barrier
Number of subjects: 28

Group type: COMPARATOR
Intervention: Coronally positioned flap
Number of subjects: 28
Study: 8072049

Group type: EXPERIMENTAL
Intervention: High-reward condition (four stars per prize)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contingent reinforcers available (all clients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-reward clients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-reward clients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed-reward clients
Number of subjects: 0
Study: 3289379

Group type: EXPERIMENTAL
Intervention: 15(R)‐15‐methyl prostaglandin E2 (Arbacet) (10 micrograms, 0.5 h before each meal and at bedtime)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31859121

Group type: EXPERIMENTAL
Intervention: Shared decision-making and patient engagement (SDM-PE) program in addition to standard treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shared decision-making and patient engagement (SDM-PE) program
Number of subjects: 0
Study: 30836052

Group type: EXPERIMENTAL
Intervention: Framing bullying in terms of resilience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Framing bullying with negative psychosocial consequences
Number of subjects: 0
Study: 28001147

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with 2 g of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo supplementation (same product without probiotics)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 66
Study: 26414563

Group type: EXPERIMENTAL
Intervention: Caloric titration method (CTM)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 167
Study: 24184430

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) - exposure in situ with therapist (T+)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) - exposure on their own following therapist preparation (T-)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both variations of CBT
Number of subjects: 146
Study: 21349747

Group type: EXPERIMENTAL
Intervention: Anti-thrombotics
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Anti-hypertensive drugs
Number of subjects: 482
Study: 19129289

Group type: EXPERIMENTAL
Intervention: Proactive integrated care (PIC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 40
Study: 17596917

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 587
Study: 15026849

Group type: EXPERIMENTAL
Intervention: Data mining methods for predicting IVS thickness clusters ('small' or 'large') using a clusterbase/rulebase combination.
Number of subjects: 63
Study: 11297240

Group type: EXPERIMENTAL
Intervention: Edatrexate 40 mg/m2 weekly with cisplatin 120 mg/m2 every 4 weeks (Schedule A)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Edatrexate 80 mg/m2 biweekly with cisplatin 60 mg/m2 every 2 weeks (Schedule B)
Number of subjects: 39
Study: 11877227

Group type: EXPERIMENTAL
Intervention: Hh-treated eyes (n = 46)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control eyes (n = 42)
Number of subjects: 78
Study: 8068835

Group type: EXPERIMENTAL
Intervention: Flexible maximum likelihood methods for assessing joint effects in case-control studies.
Number of subjects: 0
Study: 3187701

Group type: EXPERIMENTAL
Intervention: Chymopapain (Discase)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo (cysteine‐edetate‐iothalamate: CEI)
Number of subjects: 173
Study: 29559386

Group type: EXPERIMENTAL
Intervention: Subthalamic deep-brain stimulation (STN DBS)
Number of subjects: 12
Study: 28259171

Group type: EXPERIMENTAL
Intervention: Low-intensity CBT intervention
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: High-intensity CBT intervention
Number of subjects: 323

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Both CBT interventions
Number of subjects: 323
Study: 26080804

Group type: EXPERIMENTAL
Intervention: Almond consumption (85 g/day) added to a National Cholesterol Education Program (NCEP) Step 1 diet (ALM) for 6 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control NCEP Step 1 diet absent nuts (CON)
Number of subjects: 45
Study: 24517062

Group type: EXPERIMENTAL
Intervention: Qiju Dihuang Oral Liquid (QDOL), 10 mL twice daily for 2 weeks, for a total of 6 courses.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine treatment (Control group).
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Risk assessment system for preeclampsia.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mean arterial pressure method.
Number of subjects: 200
Study: 21942915

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19428189

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) readiness
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Perception of Problems (PP)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Taking Action (TA)
Number of subjects: 267
Study: 17076604

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg 1 hour before surgery and 12 hours after the first dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg 1 hour before surgery and 8 hours after the first dose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 20
Study: 14756620

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral self-help treatment
Number of subjects: 109

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 109
Study: 11319249

Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Soft insoles
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study: 8732400

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 29

Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 29
Study: 2191854

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 364037

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D dietary supplement
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 46
Study: 31712967

Group type: EXPERIMENTAL
Intervention: Integrative intervention to prevent youth problem gambling
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study: 31129065

Group type: EXPERIMENTAL
Intervention: Starting antiplatelet therapy
Number of subjects: 525

Group type: COMPARATOR
Intervention: Avoiding antiplatelet therapy
Number of subjects: 525
Study: 28756569

Group type: EXPERIMENTAL
Intervention: Intratympanic corticosteroids (administered three times every other day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral corticosteroids
Number of subjects: 35
Study: 25801204

Group type: EXPERIMENTAL
Intervention: Culturally appropriate interventions to reduce tobacco use, increase physical activity, and improve dietary intake delivered in intervention areas.
Number of subjects: 15726

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 15726
Study: 25274428

Group type: EXPERIMENTAL
Intervention: MPH-MLR 80 mg once daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: IR methylphenidate 25 mg three times daily
Number of subjects: 26
Study: 22342396

Group type: EXPERIMENTAL
Intervention: 3-day albendazole therapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 15-day albendazole therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Albendazole therapy (both durations)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Seizure recurrence
Number of subjects: 105
Study: 20837499

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 25
Study: 18055663

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-help condition
Number of subjects: 60
Study: 15623768

Group type: EXPERIMENTAL
Intervention: Glasses only
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Full treatment with glasses and occlusion
Number of subjects: 177

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 177
Study: 11854583

Group type: EXPERIMENTAL
Intervention: Injured subjects (MBI)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 84
Study: 10197852

Group type: EXPERIMENTAL
Intervention: 12-week course of 300 mg of cyproterone acetate daily followed by surgery (CPA)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Radical prostatectomy alone (Sx)
Number of subjects: 213
Study: 8879348

Group type: EXPERIMENTAL
Intervention: Enalapril (mean daily dose of 13 mg)
Number of subjects: 50
Study: 1521676

Group type: EXPERIMENTAL
Intervention: Vivida (500 mg/day for 90 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (500 mg/day for 90 days)
Number of subjects: 30
Study: 6097571

Group type: EXPERIMENTAL
Intervention: 20 g wheat bran
Number of subjects: 23

Group type: COMPARATOR
Intervention: 20 g Rice Krispies (low-fibre food)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Zinc alone
Number of subjects: 23
Study: 30768486

Group type: EXPERIMENTAL
Intervention: Condoms
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 611
Study: 29808537

Group type: EXPERIMENTAL
Intervention: Postural taping device used at home for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 27573987

Group type: EXPERIMENTAL
Intervention: New presentation strategy for HAI data
Number of subjects: 61

Group type: COMPARATOR
Intervention: Current CMS presentation strategy for HAI data
Number of subjects: 61
Study: 24953249

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) for 60 minutes before 30 minutes of physical therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group with 30 minutes of physical therapy alone
Number of subjects: 16
Study: 22577067

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation plus physical rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19454639

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) plus 10 mg/d of zolpidem
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combined therapy (CBT plus zolpidem) followed by CBT alone
Number of subjects: 160

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) alone during maintenance
Number of subjects: 160

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) plus zolpidem during maintenance
Number of subjects: 160
Study: 17488903

Group type: EXPERIMENTAL
Intervention: Infection after 6 months of pregnancy
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Infection before 4 months of pregnancy
Number of subjects: 1190
Study: 15219195

Group type: EXPERIMENTAL
Intervention: GPIIb-IIIa antagonists (abciximab)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (STEMI patients treated by PTCA without GPIIb-IIIa antagonist)
Number of subjects: 50
Study: 12217810

Group type: EXPERIMENTAL
Intervention: Low dose anti-thymocyte globulin (ATG) as first-line treatment within 14 days of diagnosis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low dose anti-thymocyte globulin (ATG) as second-line therapy more than 14 days after diagnosis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low dose anti-thymocyte globulin (ATG) early treatment group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low dose anti-thymocyte globulin (ATG) late treatment group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Concurrent control group (not treated with ATG)
Number of subjects: 28